therapeutic option for diuretic resistant patients with advanced heart failure and major volume overload. Whilst the recently reported CARRESS-HF trial was negative, by definition that patient group were not diuretic resistant. Our promising results suggest UF merits further study; in particular it may have a significant impact on length of hospital stay with associated health economic benefit in the UK.

## REFERENCE

 Bart BA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296–304.

ULTRAFILTRATION: A NEW THERAPEUTIC OPTION FOR UK PATIENTS WITH END-STAGE HEART FAILURE

P J Cowburn, J Masters, D Kelly University Hospital Southampton; Hampshire Hospitals NHS Foundation Trust

doi:10.1136/heartinl-2013-304019.14

014

Ultrafiltration (UF) is a recognised treatment option for diuretic resistant heart failure. Ultrafiltration may have potential benefits over diuretic therapy: the rate and volume of fluid removed can be carefully controlled, it does not cause neurohormonal activation and leads to improved sodium loss. However the recently reported CARRESS-HF study suggested that UF offered no benefit to a patient group with worsening renal function; stepped diuretic therapy led to a similar weight loss (~5.5 kg) and without the short-term deterioration seen in renal function with UE.1 We began an ultrafiltration programme in September 2010 and now report our early experience. We have treated 22 patients with a mean age of 71 years (range 41-93). 64% of patients had ischaemic heart disease and 50% were in AF. Mean systolic blood pressure prior to undertaking UF was 111 mm Hg (range 89-140), however seven of these patients required additional support with dopamine. Mean weight (±SD) prior to UF was 97±21 kg. Mean UF time was 83±36 h with a mean weight loss of  $10\pm5~kg$  during UF (p<0.01). Renal function deteriorated transiently during UF though there was no significant effect on renal function during the hospital stay as a whole. Mean creatinine on admission was 202±117, pre UF was 165±58, post UF was  $187\pm79$  (p<0.05, pre vs post) and on discharge was 173 ±63 μmol/l, respectively. Serum potassium rose from 4.22  $(\pm 0.45)$  to 4.68  $(\pm 0.62)$  mmol/l (p<0.01). Mean weight loss during the hospital stay was 15±7 kg. All patients survived to hospital discharge; however 10 patients have subsequently died during a mean follow up of 316±254 days. Given the very advanced nature of these patients' disease this was not unexpected. Mean length of stay was long at 26 days (range 8-68), however patients were in hospital for a mean of 8±24 days before UF was commenced. Ultrafiltration is an additional

A14